LCI699
LCI699(Osilodrostat) is a potent inhibitor of 11-hydroxylase, an enzyme catalyzing the final step of cortisol synthesis.
LCI699 also inhibits aldosterone synthase (CYP11B2) other than CYP11B1.
LCI699 is a potent inhibitor of 11-hydroxylase (CYP11B1), the enzyme that catalyzes the final step of cortisol synthesis, and has a half-life of 4 hours. It decreases blood pressure (BP) in patients with essential hypertension and primary aldosteronism. Treatment with LCI699 is well tolerated, it is demonstrated efficacy with a satisfactory safety and tolerability profile in the proof-of-concept study in Cushing's disease. The administration of LCI699, up to 1.0 mg BID, effectively and safely inhibits aldosterone synthase in patients with primary aldosteronism.
For research use only. We do not sell to patients.
Chemical Information
| Name | LCI699 |
|---|---|
| Iupac Chemical Name | LCI699 |
| Synonyms | Osilodrostat |
| Molecular Formula | C13H10FN3 |
| Molecular Weight | 227.24 |
| InChiKey | |
| InChi | |
| CAS Number | 928134-65-0 |
| Related CAS |
Ordering Information
| Packaging | Price | Availability | Purity | Shipping Time |
|---|---|---|---|---|
| Bulk | Enquiry | Enquiry | Enquiry |
| Formulation | crystalline solid |
|---|---|
| Purity | 98% |
| Storage | 3 years -20ºCpowder |
| Solubility | Soluble in DMSO |
| Handling | |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. |
| HS Code |
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |
Chemical Structure
